Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.47 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10407522 | 0.89 | AKR1C3 (0.48) | AKR1C3NOTUMKMT2AALDH1A3BCL2A1 | |
| SCHEMBL29931936 | 0.84 | ALDH1A1 (0.59) | KMT2AALDH1A1LMNAHTTMAPK1 | |
| SCHEMBL17543687 | 0.84 | ALDH1A1 (0.59) | KMT2AALDH1A1LMNAHTTMAPK1 | |
| SCHEMBL8911623 | 0.81 | ALDH1A3 (0.45) | NOTUMKMT2AALDH1A3MEN1MAPT | |
| SCHEMBL6309417 | 0.79 | ALDH1A1 (0.63) | AKR1C3NOTUMKMT2AALDH1A3MEN1 | |
| SCHEMBL17543923 | 0.79 | CHRM1 (0.49) | KMT2AALDH1A3MEN1MAPTALDH1A1 | |
| SCHEMBL17542897 | 0.78 | ALDH1A1 (0.44) | KMT2AALDH1A3MEN1MAPTALDH1A1 | |
| SCHEMBL17543217 | 0.78 | ALDH1A3 (0.42) | KMT2AALDH1A3MEN1MAPTHTR1A | |
| SCHEMBL9831059 | 0.77 | ADRA1B (0.51) | NOTUMKMT2AMEN1MAPTHTR1A | |
| SCHEMBL22653981 | 0.76 | AKR1C3 (0.49) | AKR1C3NOTUMALDH1A3BCL2A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106795117-B | Heterobicyclic compounds and their use for the treatment of tuberculosis | 大塚制药株式会社 | 2020-06-26 | — | — | CN | disclosed |
| US-10464926-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-11-05 | — | — | US | disclosed |
| EP-3186240-B1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2019-06-12 | — | — | EP | disclosed |
| US-20180312488-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-11-01 | — | — | US | disclosed |
| US-10053446-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-08-21 | — | — | US | disclosed |
| US-20170253576-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-09-07 | — | — | US | disclosed |
| EP-3186240-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016031255-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-03-03 | — | — | WO | disclosed |
| EP-0240398-B1 | DISSYMMETRICAL 1,4-DIHYDROPYRIDINE-3,5-DICARBOXYLIC-ACID DERIVATIVES, PREPARATION PROCESSES AND THERAPEUTICAL USE | FOURNIER INNOVATION ET SYNERGIE (FR) | 1991-05-15 | — | — | EP | disclosed |
| US-4900833-A | HYPOTENSIVE AGENTS | SOCIETE DE RECHERCHES INDUSTRIES (S.O.R.I.) (FR) | 1990-02-13 | — | — | US | disclosed |
| US-4806544-A | ENANTIOMORPHS, RACEMIC MIXTURES, HYPOTENSIVE AGENTS, CARDIOV LAR DISORDERS | FOURNIER INNOVATION ET SYNERGIE (FR) | 1989-02-21 | — | — | US | disclosed |
| EP-0240398-A1 | Dissymmetrical 1,4-dihydropyridine-3,5-dicarboxylic-acid derivatives, preparation processes and therapeutical use | FOURNIER INNOVATION ET SYNERGIE (FR) | 1987-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053446-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | FNTB, SLC11A2, TBCD | AKR1C3 4022/4885NOTUM 1610/4885KMT2A 2525/4885 |
| US-10464926-B2 | Heterobicyclic compounds and their use for the treatment of tuberculosis | FNTB, SLC11A2, TBCD | AKR1C3 4022/4885NOTUM 1610/4885KMT2A 2525/4885 |
| US-20180312488-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | FNTB, SLC11A2, TBCD | AKR1C3 4022/4885NOTUM 1610/4885KMT2A 2525/4885 |
| US-20170253576-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF TUBERCULOSIS | FNTB, SLC11A2, TBCD | AKR1C3 4022/4885NOTUM 1610/4885KMT2A 2525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.